

Special Issue

Recent Developments in Cancer Systems Biology

Message from the Guest Editors

Cancer is a complex disease that involves multifaceted mechanisms at transcriptional, translational, and biochemical levels. In addition, several molecules become important players in cancer progression and provide conducive environment for protein–protein interactions, metabolite cross-talk, and cell signaling. Studying such molecules may offer discovery of biomarkers, targetable clues for potentially repurposing drugs, as well as insights for developing predictive models of prognosis and improving cancer-free survival in patients. Systems biology has undoubtedly emerged as an integrative tool to achieve such advances. The *Journal of Personalized Medicine* is now opening a Special Issue that is fully devoted to ideas and research that build a strong foundation of Systems Biology in cancer research, with a call for papers involving basic, translational, and clinical research on this topic.

Guest Editors

Dr. Raghu Sinha


Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA, USA

Dr. Kazim Yalcin Arga

Department of Bioengineering, Marmara University, 34722 Goztepe, Istanbul, Turkey

Deadline for manuscript submissions

closed (10 December 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed




mdpi.com/si/46812

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).